

Supporting Information For:

Organocatalytic asymmetric multicomponent reactions of aromatic aldehydes and anilines with β -ketoesters: A facile and atom-economical access to chiral tetrahydropyridines

*Xuejian Li, Yanyan Zhao, Haijun Qu, Zhenjun Mao, and Xufeng Lin**

Department of Chemistry, Zhejiang University, Hangzhou 310027, P. R. China

Email: lxfok@zju.edu.cn

CONTENTS

1. General Information	S2
2. General Procedure	S2
3. References	S9
4. ^1H and ^{13}C NMR spectra	S10
5. Absolute configuration assignments and a proposed mechanism	S24
6. HPLC spectra	S27

1. General Information

All reactions were carried out in oven-dried glassware with magnetic stirring under dry argon atmosphere unless otherwise mentioned. The corresponding carboxylic acid is an efficient catalyst for this reaction and the ee immediately drops when this acid is present, so aldehydes were all freshly distilled or dissolved in diethyl ether, washed with saturated aqueous NaHCO₃ for three times, dried over Na₂SO₄, filtered through a pad of silica, concentrated, and subjected to high vacuum (<0.2 Torr) before use. Solvents were purified and dried according to standard methods prior to use. Powdered 4Å molecular sieves were activated at 200 °C for 2 h under vacuum (<0.2 Torr). Catalysts **5a-5d** were prepared according to the methods reported in the literature^[1] and washed with 4N HCl before use.


¹H NMR spectra were recorded on 400 MHz or 500 MHz spectrometer. The chemical shifts were reported relative to internal standard TMS (0) in CDCl₃ or 2.5 in DMSO-d₆. The following abbreviations were used to describe peak patterns where appropriate: br=broad, s=singlet, d=doublet, t=triplet, q=quartet, m=multiplet. Coupling constants were reported in Hertz (Hz). ¹³C NMR spectra were recorded on 100 MHz or 125 MHz spectrometer, referred to the internal solvent signals (77.0 for CDCl₃ or 40.0 for DMSO-d₆). Infrared spectra were recorded on a ATR-FTIR spectrometer. Optical rotations were determined using a Perkin Elmer Model 341 polarimeter at 20 °C. The enantiomeric excesses (ee) were determined by chiral HPLC analysis on Daicel Chiralpak AD-H and Chiralcel OD-H columns. HRMS were obtained using EI ionization.

2. General Procedure

General Procedure for synthesis of chiral functionalized Tetrahydropyridines **4**.


To a solution of aromatic aldehyde **1** (0.2 mmol), aniline **2** (0.2 mmol) and β-ketoester **3** (0.1 mmol) in toluene (3 mL) was added powdered 4Å molecular sieves (0.1 g) and the chiral SPINOL-phosphoric acid **5c** (0.01 mmol). The resulting mixture was stirred under an argon atmosphere at -30 °C for 3 days. Solvent was removed *in vacuum*, and the residue was purified by flash chromatography on silica gel (petroleum ether/ethyl acetate) to afford the corresponding tetrahydropyridine **4**.

(2R,6S)-methyl 2,6-bis(4-nitrophenyl)-1-phenyl-4-(phenylamino)-1,2,5,6-tetrahydropyridine-3-carboxylate (**4a**)




According to general procedure: the product was obtained as yellow solid, mp 254-256 °C, from flash chromatography (hexane/EtOAc = 10:1 to 6:1), >99% ee. HPLC analysis: Chiralpak OD-H (hexane/i-PrOH = 85/15, 0.8 mL/min), t_R (major) 23.0 min, t_R (minor) 31.6 min. [α]_D²⁰ = -7° (c = 0.27, CHCl₃), ¹H NMR (400 MHz, CDCl₃) δ (ppm) 10.28 (s, 1H), 8.15 (t, J = 9.3 Hz, 4H), 7.50 (d, J = 8.6 Hz, 2H), 7.29 (d, J = 8.6 Hz, 2H), 7.19 (dd, J = 10.2, 5.2 Hz, 3H), 7.10 (t, J = 7.9 Hz, 2H), 6.70 (t, J = 7.3 Hz, 1H), 6.48 (s, 1H), 6.43 (m, 3H), 6.39 (s, 1H), 5.28 (s, 1H), 3.97 (s, 3H), 2.88 (d, J = 4.0 Hz, 2H); ¹³C NMR (100 MHz, CDCl₃) δ (ppm) 167.89, 155.45, 151.50, 149.68, 147.26, 146.78, 145.70, 137.06, 129.31, 129.18, 127.35, 127.29, 126.41, 125.46, 123.90, 123.73, 117.63, 112.83, 96.60, 57.29, 55.14, 51.44, 33.53; IR (KBr) γ, 3448, 3244, 2946, 1654, 1595, 1519. 1500, 1346, 749 cm⁻¹; HRMS (EI-TOF): calcd for C₃₁H₂₆N₄O₆ 550.1852, found 550.1862.

(2R,6S)-methyl 2,6-bis(3-nitrophenyl)-1-phenyl-4-(phenylamino)-1,2,5,6-tetrahydropyridine-3-carboxylate (4b)



According to general procedure: the product was obtained as yellow solid, mp 218-219 °C, from flash chromatography (hexane/EtOAc = 10:1 to 6:1), 90% ee. HPLC analysis: Chiralpak AD-H (hexane/i-PrOH = 80/20, 1.0 mL/min), t_R (major) 8.8 min, t_R (minor) 30.9 min, [α]_D²⁰ = -4° (c = 0.32, CHCl₃); ¹H NMR (400 MHz, CDCl₃) δ (ppm) 10.30 (s, 1H), 8.21 (s, 1H), 8.12 (dd, J = 8.7 Hz, 5.1, 2H), 7.94 (s, 1H), 7.66 (d, J = 7.6 Hz, 1H), 7.52-7.41 (m, 3H), 7.11 (ddd, J = 21.9, 10.3, 6.1 Hz, 5H), 6.70 (t, J = 7.3 Hz, 1H), 6.49 (s, 1H), 6.44 (d, J = 8.2 Hz, 2H), 6.39 (dd, J = 6.5, 2.6 Hz, 2H), 5.33 (s, 1H), 3.98 (s, 3H), 2.88 (d, J = 3.9 Hz, 2H); ¹³C NMR (100 MHz, CDCl₃) δ (ppm) 167.99, 155.50, 148.59, 148.50, 146.24, 145.66, 144.37, 137.06, 132.51, 129.66, 129.31, 129.20, 126.55, 125.62, 122.46, 121.84, 121.47, 121.32, 117.65, 113.01, 96.69, 56.98, 55.10, 51.43, 33.70; IR (KBr) γ, 3452, 3238, 2949, 1654, 1652, 1616. 1528, 1497, 1349, 1255, 1051 cm⁻¹; HRMS (EI-TOF): calcd for C₃₁H₂₆N₄O₆ 550.1852, found 550.1846.


(2R,6S)-methyl 2,6-bis(2-nitrophenyl)-1-phenyl-4-(phenylamino)-1,2,5,6-tetrahydropyridine-3-carboxylate (4c)



According to general procedure: the product was obtained as yellow solid, mp 232-234 °C, from flash chromatography (hexane/EtOAc = 10:1 to 6:1), 87% ee. HPLC analysis: Chiralpak OD-H (hexane/i-


PrOH = 90/10, 0.8 mL/min), t_R (major) 19.4 min, t_R (minor) 25.4min, $[\alpha]_D^{20} = -2^\circ$ ($c = 0.29$, CHCl_3); ^1H NMR (400 MHz, CDCl_3) δ (ppm) 10.46 (s, 1H), 7.94 (d, $J = 7.8$ Hz, 1H), 7.66-7.68 (d, $J = 8$ Hz, 1H), 7.45-7.48 (m, 3H), 7.31-7.40 (m, 3H), 7.15-7.20 (m, 3H), 7.10 (t, $J = 7.6$ Hz, 2H), 6.85 (s, 1H), 6.73 (t, 14.6 Hz, 1H), 6.68 (d, $J = 8.2$ Hz, 2H), 6.48 (d, $J = 6.8$ Hz, 2H), 6.00 (s, 1H), 3.79 (s, 3H), 3.02 (dd, $J = 6, 5.6$ Hz, 1H), 2.90 (dd, $J = 3.2, 2.6$ Hz, 1H); ^{13}C NMR (100 MHz, CDCl_3) δ (ppm) 168.08, 155.67, 150.05, 148.21, 145.66, 137.72, 137.30, 137.26, 133.50, 131.60, 129.46, 129.21, 129.17, 128.49, 128.19, 127.82, 126.36, 125.68, 125.15, 124.70, 118.84, 115.13, 94.81, 53.58, 52.91, 51.04, 31.28; IR (KBr) γ , 3448, 2944, 1653, 1597, 1529, 1367, 1498, 1261, 745 cm^{-1} ; HRMS (EI-TOF): calcd for $\text{C}_{31}\text{H}_{26}\text{N}_4\text{O}_6$ 550.1852, found 550.1854.

(2R,6S)-methyl 2,6-bis(4-cyanophenyl)-1-phenyl-4-(phenylamino)-1,2,5,6-tetrahydropyridine-3-carboxylate(4d)



According to general procedure: the product was obtained as white solid, mp 185-187°C, from flash chromatography (hexane/EtOAc = 10:1 to 6:1), 87% ee. HPLC analysis: Chiralpak AD-H (hexane/i-PrOH = 65/35, 1 mL/min), t_R (major) 7.7 min, t_R (minor) 19.9 min, $[\alpha]_D^{20} = 5.4^\circ$ ($c = 0.61$, CHCl_3); ^1H NMR (400 MHz, CDCl_3) δ (ppm) 10.26 (s, 1H), 7.57 (t, $J = 8.2$ Hz, 4H), 7.43 (d, $J = 7.9$ Hz, 2H), 7.24 (t, $J = 7.1$ Hz, 2H), 7.17 (d, $J = 7.1$ Hz, 3H), 7.08 (t, $J = 7.7$ Hz, 2H), 6.68 (t, $J = 7.1$ Hz, 1H), 6.41 (dd, $J = 14.1, 8.6$ Hz, 5H), 5.20 (s, 1H), 3.94 (s, 3H), 2.82 (d, $J = 2.7$ Hz, 2H); ^{13}C NMR (100 MHz, CDCl_3) δ (ppm) 167.93, 155.51, 149.36, 147.72, 145.79, 137.11, 132.63, 132.34, 129.23, 129.11, 127.27, 127.11, 126.34, 125.49, 118.84, 118.59, 117.41, 112.75, 111.20, 110.46, 96.70, 57.47, 55.10, 51.32, 33.43; IR (KBr) γ , 3059, 2950, 2227, 1660, 1593, 1500, 1319, 1256, 1891, 745 cm^{-1} ; HRMS (EI-TOF): calcd for $\text{C}_{33}\text{H}_{26}\text{N}_4\text{O}_6$ 510.12056, found 510.2066.


(2R,6S)-methyl 1,2,6-triphenyl-4-(phenylamino)-1,2,5,6-tetrahydropyridine-3-carboxylate(4e)



According to general procedure: the product was obtained as white solid, mp 200-202 °C, from flash chromatography (hexane/EtOAc = 10:1 to 6:1), 88% ee. HPLC analysis: Chiralpak AD-H (hexane/i-PrOH = 85/15, 0.8 mL/min), t_R (major) 6.6 min, t_R (minor) 21.2 min, $[\alpha]_D^{20} = +29^\circ$ ($c = 0.09$, CHCl_3); ^1H NMR (400 MHz, CDCl_3) δ (ppm) 10.28 (s, 1H), 7.30 (m, 7H), 7.20 (dd, $J = 12.7, 6.2$ Hz, 3H), 7.07 (m, 5H), 6.61 (dd, $J = 14.0, 7.0$ Hz, 1H), 6.53 (t, $J = 8.2$ Hz, 2H), 6.47 (d, $J = 9.1$ Hz, 1H), 6.28 (d, $J = 7.2$ Hz, 2H), 5.16 (s, 1H), 3.94 (d, $J = 6.5$ Hz, 3H), 2.83 (m, 2H); ^{13}C NMR (100 MHz,


CDCl₃) δ (ppm) 168.48, 156.20, 146.84, 143.81, 142.63, 137.70, 128.81, 128.77, 128.56, 128.17, 127.07, 126.55, 126.28, 125.77, 125.70, 116.08, 112.82, 97.82, 58.10, 55.00, 50.96, 33.53. IR (KBr) γ , 3246, 3058, 2948, 1656, 1580, 1500, 1449, 1375, 1324, 1072 cm⁻¹; HRMS (EI-TOF): calcd for C₃₁H₂₈N₂O₂ 460.2151, found 460.2154.

(2R,6S)-methyl 1-(4-chlorophenyl)-4-((4-chlorophenyl)amino)-2,6-di-p-tolyl-1,2,5,6-tetrahydropyridine-3-carboxylate (4f)



According to general procedure: the product was obtained as white solid, mp 234-236 °C, from flash chromatography (hexane/EtOAc = 10:1 to 6:1), 41% ee. HPLC analysis: Chiralpak AD-H (hexane/i-PrOH = 80/20, 0.8 mL/min), t_R (major) 7.9 min, t_R (minor) 18.7 min, $[\alpha]_D^{20}$ = 8.6° (c = 0.38, CHCl₃); ¹H NMR (400 MHz, CDCl₃) δ (ppm) 10.19 (s, 1H), 7.14 (d, J = 7.1 Hz, 2H), 7.12 – 6.99 (m, 8H), 6.97 (d, J = 8.3 Hz, 2H), 6.42 (d, J = 8.2 Hz, 2H), 6.32 (s, 1H), 6.18 (d, J = 7.8 Hz, 2H), 5.06 (s, 1H), 3.89 (d, J = 24.2 Hz, 3H), 2.99 – 2.60 (m, 2H), 2.32 (d, J = 9.6 Hz, 6H); ¹³C NMR (100 MHz, CDCl₃) δ (ppm) 168.45, 155.52, 145.53, 140.14, 139.14, 137.01, 136.43, 136.08, 131.26, 129.41, 129.03, 128.94, 128.63, 126.99, 126.38, 126.20, 121.03, 113.96, 98.58, 57.99, 55.06, 51.11, 33.45, 21.06, 20.97; IR (KBr) γ , 3241, 3173, 2950, 1659, 1574, 1494 1321, 1257, 1188, 1092, 1072 cm⁻¹; HRMS (EI-TOF): calcd for C₃₃H₃₀Cl₂N₂O₂ 556.1684, found 556.1676.


(2R,6S)-methyl 1-(4-bromophenyl)-4-((4-bromophenyl)amino)-2,6-diphenyl-1,2,5,6-tetrahydropyridine-3-carboxylate (4g)



According to general procedure: the product was obtained as white solid, mp 220-214 °C, from flash chromatography (hexane/EtOAc = 10:1 to 6:1), 97% ee. HPLC analysis: Chiralpak OD-H (hexane/i-PrOH = 90/10, 0.7 mL/min), t_R (major) 7.6 min, t_R (minor) 14.6 min, $[\alpha]_D^{20}$ = +29° (c = 0.34, CHCl₃); ¹H NMR (400 MHz, CDCl₃) δ (ppm) 11.92 (s, 1H), 7.35-7.18 (m, 11H), 7.13 (dd, J = 18.4, 8.1 Hz, 5H), 6.41 (d, J = 8.9 Hz, 2H), 5.94 (s, 1H), 5.09 (t, J = 4.8 Hz, 1H), 3.89 (s, 3H), 3.10 (dd, J = 16.4, 5.8 Hz, 1H), 2.71 (dd, J = 16.3, 4.2 Hz, 1H); ¹³C NMR (100 MHz, CDCl₃) δ (ppm) 171.05, 170.35, 145.93, 141.99, 141.56, 131.96, 131.40, 128.69, 128.43, 127.31, 127.08, 126.61, 126.22, 117.72, 114.50, 110.41, 101.86, 57.37, 56.89, 51.91, 36.63; IR (KBr) γ , 3367, 3060, 2953, 1660, 1591,


1493. 1446, 1372, 1324, 1072 cm^{-1} ; HRMS (EI-TOF): calcd for $\text{C}_{31}\text{H}_{26}\text{Br}_2\text{N}_2\text{O}_6$ 616.0361, found 616.0361.

(2R,6S)-methyl 1-(4-bromophenyl)-4-((4-bromophenyl)amino)-2,6-bis(4-chlorophenyl)-1,2,5,6-tetrahydropyridine-3-carboxylate (4h)



According to general procedure: the product was obtained as white solid, mp 169-171 $^{\circ}\text{C}$, from flash chromatography (hexane/EtOAc = 10:1 to 6:1), 91% ee. HPLC analysis: Chiralpak AD-H (hexane/i-PrOH = 75/25, 1.0 mL/min), t_R (major) 4.8 min, t_R (minor) 14.4 min, $[\alpha]_D^{20} = +30^{\circ}$ ($c = 0.34$, CHCl_3); ^1H NMR (400 MHz, CDCl_3) δ (ppm) 10.20 (s, 1H), 7.25 (dd, $J = 8, 3.2$ Hz, 6H), 7.15 (d, $J = 12.8$ Hz, 2H), 7.12 (d, $J = 8.8$ Hz, 2H), 7.03 (d, $J = 7.6$ Hz, 2H), 6.31 (d, $J = 9.2$ Hz, 2H), 6.26 (d, $J = 5.2$ Hz, 2H), 6.24 (s, 1H), 5.05 (d, $J = 3.2$ Hz, 1H), 3.92 (s, 3H), 2.81 (dd, $J = 5.6, 5.6$ Hz, 1H), 2.69 (d, $J = 14.8$ Hz, 1H); ^{13}C NMR (101 MHz, CDCl_3) δ (ppm) 168.12, 155.13, 145.34, 141.44, 140.17, 136.57, 133.21, 132.43, 132.13, 131.72, 128.92, 128.52, 127.83, 127.61, 127.12, 119.47, 114.53, 109.12, 98.05, 57.34, 54.79, 51.32, 33.49; IR (KBr) γ , 3446, 2943, 1658, 1608, 1587, 1489, 1319, 1255, 1090, 1069 cm^{-1} ; HRMS (EI-TOF): calcd for $\text{C}_{31}\text{H}_{24}\text{Br}_2\text{Cl}_2\text{N}_2\text{O}_2$ 683.9582, found 683.9577.


(2R,6S)-methyl 1-(4-bromophenyl)-4-(4-bromophenylamino)-2,6-bis(4-cyanophenyl)-1,2,5,6-tetrahydropyridine-3-carboxylate (4i)



According to general procedure: the product was obtained as white solid, mp 242-243 $^{\circ}\text{C}$, from flash chromatography (hexane/EtOAc = 10:1 to 6:1), 92% ee. HPLC analysis: Chiralpak AD-H (hexane/i-PrOH = 55/45, 1 mL/min), t_R (major) 6.2 min, t_R (minor) 26.9min, $[\alpha]_D^{20} = -6.3^{\circ}$ ($c = 0.67$, CHCl_3); ^1H NMR (400 MHz, CDCl_3) δ (ppm) 10.22 (s, 1H), 7.59 (dd, $J=8.1, 3.8$, 4H), 7.39 (d, $J=8.2$, 2H), 7.30 (d, $J=8.5$, 2H), 7.21 (d, $J=8.2$, 2H), 7.16 (d, $J=8.9$, 2H), 6.35 (s, 1H), 6.29 (s, 1H), 6.27 (d, $J=2.4$, 2H), 6.24 (s, 1H), 5.16 (s, 1H), 3.95 (s, 3H), 2.79 (dd, $J=15.4, 3.9$, 2H); ^{13}C NMR (101 MHz, CDCl_3) δ (ppm) 167.85, 154.74, 148.53, 146.99, 144.79, 136.18, 132.64, 132.41, 132.36, 132.04, 127.19, 127.05, 126.91, 119.90, 118.69, 118.38, 114.45, 111.65, 110.86, 109.86, 97.35, 57.54, 55.27, 51.57, 33.38; IR (KBr) γ , 3238, 2959, 2230, 1659, 1611, 1492, 1254, 1191, 1069, 736 cm^{-1} ; HRMS (EI-TOF): calcd for $\text{C}_{33}\text{H}_{24}\text{Br}_2\text{N}_4\text{O}_6$ 666.0266, found 666.0621.


(2R,6S)-ethyl 2,6-bis(4-nitrophenyl)-1-phenyl-4-(phenylamino)-1,2,5,6-

tetrahydropyridine-3-carboxylate (4j)




According to general procedure: the product was obtained as yellow solid, mp 247-249 °C, from flash chromatography (hexane/EtOAc = 10:1 to 6:1), >99% ee. HPLC analysis: Chiralpak OD-H (hexane/i-PrOH = 90/10, 0.7 mL/min), t_R (major) 32.7 min, t_R (minor) 42.5 min, $[\alpha]_D^{20} = -35.3^\circ$ ($c = 0.34$, CHCl_3); ^1H NMR (400 MHz, CDCl_3) δ (ppm) 10.33 (s, 1H), 8.15 (dd, $J = 12.8, 8.5$ Hz, 4H), 7.52 (d, $J = 8.6$ Hz, 2H), 7.29 (d, $J = 8.5$ Hz, 2H), 7.26 (s, 1H), 7.17 (d, $J = 6.9$ Hz, 2H), 7.10 (t, $J = 7.8$ Hz, 2H), 6.71 (t, $J = 7.1$ Hz, 1H), 6.48 (s, 1H), 6.44 (s, 1H), 6.41 (s, 2H), 6.39 (s, 1H), 5.27 (s, 1H), 4.43 (m, 2H), 2.87 (d, $J = 3.7$ Hz, 2H), 1.49 (t, $J = 7.1$ Hz, 3H); ^{13}C NMR (100 MHz, CDCl_3) δ (ppm) 167.58, 155.27, 151.64, 149.73, 147.30, 146.79, 145.78, 137.17, 129.35, 129.19, 127.33, 126.34, 125.42, 123.91, 123.75, 117.67, 112.92, 96.89, 60.24, 57.34, 55.20, 33.58, 14.77; IR (KBr) γ , 2971, 2931, 1653, 1594, 1581, 1519, 1501, 1346, 1246, 750 cm^{-1} ; HRMS (EI-TOF): calcd for $\text{C}_{32}\text{H}_{28}\text{N}_4\text{O}_6$ 564.2009, found 564.2015.

(2R,6S)-isopropyl 2,6-bis(4-nitrophenyl)-1-phenyl-4-(phenylamino)-1,2,5,6-tetrahydropyridine-3-carboxylate (4k)




According to general procedure: the product was obtained as yellow solid, mp 198-200 °C, from flash chromatography (hexane/EtOAc = 10:1 to 6:1), 96% ee. HPLC analysis: Chiralpak OD-H (hexane/i-PrOH = 85/15, 0.8 mL/min), t_R (major) 13.1 min, t_R (minor) 17.7 min, $[\alpha]_D^{20} = -50.8^\circ$ ($c = 0.81$, CHCl_3); ^1H NMR (400 MHz, CDCl_3) δ (ppm) 10.37 (s, 1H), 8.18 (s, 1H), 8.15 (d, $J = 6.2$ Hz, 2H), 8.12 (s, 1H), 7.52 (d, $J = 8.6$ Hz, 2H), 7.29 (s, 1H), 7.27 (d, $J = 4.8$ Hz, 2H), 7.14 (m, 5H), 6.71 (t, $J = 7.2$ Hz, 1H), 6.42 (dd, $J = 15.6, 9.0$ Hz, 5H), 5.30 (m, 2H), 2.88 (d, $J = 3.8$ Hz, 2H), 1.48 (d, $J = 6.2$ Hz, 3H), 1.43 (d, $J = 6.2$ Hz, 3H); ^{13}C NMR (100 MHz, CDCl_3) δ (ppm) 167.16, 155.06, 151.71, 149.73, 147.23, 146.71, 145.81, 137.20, 129.33, 129.15, 127.29, 126.20, 125.31, 123.86, 123.71, 117.64, 112.97, 97.14, 67.63, 57.27, 55.21, 33.58, 22.33, 22.24; IR (KBr) γ , 3451, 2974, 1654, 1593, 1519, 1501, 1248, 1180, 1108, 751 cm^{-1} ; HRMS (EI-TOF): calcd for $\text{C}_{33}\text{H}_{30}\text{N}_4\text{O}_6$ 578.2165, found 578.2171.

(2R,6S)-tert-butyl 2,6-bis(4-nitrophenyl)-1-phenyl-4-(phenylamino)-1,2,5,6-tetrahydropyridine-3-carboxylate (4l)



According to general procedure: the product was obtained as yellow solid, mp 219-221 °C, from flash chromatography (hexane/EtOAc = 10:1 to 6:1), 91% ee. HPLC analysis: Chiralpak AD-H (hexane/i-PrOH = 80/20, 1 mL/min), t_R (major) 5.0 min, t_R (minor) 13.1 min; >99% ee (after single recrystallization from hexane/EtOAc), $[\alpha]_D^{20} = -88^\circ$ ($c = 0.34$, CHCl_3); ^1H NMR (400 MHz, CDCl_3) δ (ppm) 10.30 (s, 1H), 8.15 (dd, $J = 17.0, 8.6$ Hz, 4H), 7.53 (d, $J = 8.6$ Hz, 2H), 7.29 (d, $J = 8.5$ Hz, 2H), 7.13 (ddd, $J = 22.3, 15.0, 7.3$ Hz, 5H), 6.71 (t, $J = 7.3$ Hz, 1H), 6.44 (d, $J = 7.7$ Hz, 3H), 6.39 (d, $J = 8.3$ Hz, 2H), 5.24 (s, 1H), 2.85 (d, $J = 4.0$ Hz, 2H), 1.66 (s, 9H); ^{13}C NMR (100 MHz, CDCl_3) δ (ppm) 167.47, 154.39, 151.84, 149.82, 147.25, 146.71, 145.87, 137.38, 129.35, 129.05, 127.32, 127.26, 126.00, 125.18, 123.83, 123.71, 117.62, 112.98, 98.37, 81.01, 57.30, 55.60, 53.40, 33.59, 28.73; IR (KBr) γ , 3451, 2968, 1650, 1593, 1522, 1501, 1340, 1250, 1063 cm^{-1} ; HRMS (EI-TOF): calcd for $\text{C}_{34}\text{H}_{32}\text{N}_4\text{O}_6$ 592.2322, found 592.2326.

(2R,5R,6S)-methyl 5-methyl-2,6-bis(4-nitrophenyl)-1-phenyl-4-(phenylamino)-1,2,5,6-tetrahydropyridine-3-carboxylate (4m)




According to general procedure: the product was obtained as yellow solid, mp 249-251 °C, from flash chromatography (hexane/EtOAc = 10:1 to 6:1), 93% ee. HPLC analysis: Chiralpak OD-H (hexane/i-PrOH = 97.5/2.5, 0.8 mL/min), t_R (major) 41.5 min, t_R (minor) 51.5 min, $[\alpha]_D^{20} = -50.8^\circ$ ($c = 0.89$, CHCl_3); ^1H NMR (400 MHz, CDCl_3) δ (ppm) 10.40 (s, 1H), 8.12 (dd, $J = 11.0, 8.8$ Hz, 4H), 7.50 (d, $J = 8.6$ Hz, 2H), 7.23 (dd, $J = 8.8, 6.3$ Hz, 5H), 7.10 (t, $J = 7.9$ Hz, 2H), 6.74 (t, $J = 7.2$ Hz, 1H), 6.54 (d, $J = 8.2$ Hz, 4H), 6.29 (s, 1H), 5.02 (s, 1H), 3.89 (s, 3H), 3.08 (dt, $J = 13.0, 6.4$ Hz, 1H), 1.13 (d, $J = 7.3$ Hz, 3H); ^{13}C NMR (100 MHz, CDCl_3) δ (ppm) 168.73, 159.53, 151.62, 150.38, 147.00, 146.57, 146.23, 137.39, 129.26, 129.12, 128.57, 127.78, 127.07, 127.95, 123.73, 123.21, 118.68, 115.35, 94.33, 63.96, 55.80, 51.33, 38.10, 19.22; IR (KBr) γ , 3366, 2950, 1661, 1516, 1506, 1346, 1247, 1108, 1013, 855, 747 cm^{-1} ; HRMS (EI-TOF): calcd for $\text{C}_{32}\text{H}_{28}\text{N}_4\text{O}_6$ 564.2009, found 564.2015.

Procedure for reduction of 4e to 7^[2]

The tetrahydropyridine **4e** (0.2 mmol) dissolved in a mixture of i-PrOH (0.5 mL) and THF (0.5 mL) was treated with an excess of sodium wire (0.05 g) and magnetically stirred 50°C for the time required

for complete reduction (5 h) as monitored by TLC. After the removal of the unreacted sodium, the reaction mixture was poured into saturated aqueous NH_4Cl (5 mL) and extracted with CH_2Cl_2 . The organic layer was dried and evaporated under reduced pressure, Column chromatographic separation of the crude material, afforded white solid 7.

((2S,3R,4S,6S)-1,2,6-triphenyl-4-(phenylamino)piperidin-3-yl)methanol (7)




The product was obtained as white solid, mp 171-173 °C, from flash chromatography (hexane/EtOAc = 10:1 to 6:1), 88% ee. HPLC analysis: Chiralpak AD-H (hexane/i-PrOH = 80/20, 0.8 mL/min), t_R (major) 8.2 min, t_R (minor) 13.5min, $[\alpha]_D^{20} = 34.5^\circ$ ($c = 0.42$, CHCl_3); ^1H NMR (400 MHz, CDCl_3) δ (ppm) 7.35 (dd, $J = 12.3, 4.3$ Hz, 4H), 7.31 (d, $J = 4.4$ Hz, 4H), 7.29-7.27 (m, 2H), 7.16-7.09 (m, 2H), 7.00 (dd, $J = 8.7, 7.3$ Hz, 2H), 6.75 (t, $J = 7.3$ Hz, 1H), 6.62 (t, $J = 7.3$ Hz, 1H), 6.46 (d, $J = 8.0$ Hz, 2H), 6.41-6.34 (m, 2H), 5.32 (d, $J = 5.1$ Hz, 1H), 5.15 (t, $J = 4.9$ Hz, 1H), 3.83 (m, 2H), 3.50 (brs, 1H), 2.84 (ddd, $J = 14.8, 6.7, 5.2$ Hz, 1H), 2.81-2.76 (m, 2 H), 2.71 (dd, $J = 10.8, 5.2$ Hz, 1H), 2.36 (ddd, $J = 14.8, 4.6, 3.6$ Hz, 1H); ^{13}C NMR (100 MHz, CDCl_3) δ (ppm) 147.85, 146.16, 143.35, 139.22, 129.25, 128.67, 128.62, 128.34, 127.20, 126.90, 126.84, 126.75, 119.03, 117.72, 115.54, 115.40, 64.95, 60.84, 56.27, 49.66, 47.74, 36.98. IR (KBr) γ , 3413, 3060, 2931, 1600, 1599, 1501, 1447, 1308, 1182, 1034, 745 cm^{-1} ; HRMS (EI-TOF): calcd for $\text{C}_{30}\text{H}_{30}\text{N}_2\text{O}$ 434.2358, found 434.2367.

3. References



- [1] F. X. Xu, D. Huang, C. Han, W. Shen, X. F. Lin, Y. G. Wang, *J. Org. Chem.* **2010**, 75, 8677-8680.
- [2] G. Bartoli, C. Cimarrelli, E. Marcantoni, G. Palmieri, and M. Petrini, *J. Org. Chem.* **1994**, 59, 5328-5335

4. ^1H and ^{13}C NMR spectra



(2R,6S)-methyl 2,6-bis(4-nitrophenyl)-1-phenyl-4-(phenylamino)-1,2,5,6-tetrahydropyridine-3-carboxylate (4a)




(2R,6S)-methyl 2,6-bis(3-nitrophenyl)-1-phenyl-4-(phenylamino)-1,2,5,6-tetrahydropyridine-3-carboxylate (4b)



(2R,6S)-methyl 2,6-bis(2-nitrophenyl)-1-phenyl-4-(phenylamino)-1,2,5,6-tetrahydropyridine-3-carboxylate (4c)





(2R,6S)-methyl2,6-bis(4-cyanophenyl)-1-phenyl-4-(phenylamino)-1,2,5,6-tetrahydropyridine-3-carboxylate (4d)








**(2R,6S)-methyl 1,2,6-triphenyl-4-(phenylamino)-1,2,5,6-tetrahydropyridine
-3-carboxylate (4e)**




(2R,6S)-methyl 1-(4-chlorophenyl)-4-((4-chlorophenyl)amino)-2,6-di-p-tolyl-1,2,5,6-tetrahydropyridine-3-carboxylate (4f)




(2R,6S)-methyl 1-(4-bromophenyl)-4-((4-bromophenyl)amino)-2,6-diphenyl-1,2,5,6-tetrahydropyridine-3-carboxylate (4g)




**(2R,6S)-methyl 1-(4-bromophenyl)-4-((4-bromophenyl)amino)-2,6-bis(4-chlorophenyl)-
1,2,5,6-tetrahydropyridine-3-carboxylate (4h)**





(2R,6S)-methyl-(4-bromophenyl)-4-(4-bromophenylamino)-2,6-bis(4-cyanophenyl)-1,2,5,6-tetrahydropyridine-3-carboxylate (4i)





(2R,6S)-ethyl 2,6-bis(4-nitrophenyl)-1-phenyl-4-(phenylamino)-1,2,5,6-tetrahydropyridine-3-carboxylate (4j)





(2R,6S)-isopropyl 2,6-bis(4-nitrophenyl)-1-phenyl-4-(phenylamino)-1,2,5,6-tetrahydropyridine-3-carboxylate (4k)





(2R,6S)-tert-butyl 2,6-bis(4-nitrophenyl)-1-phenyl-4-(phenylamino)-1,2,5,6-tetrahydropyridine-3-carboxylate (4I)



(2R,5R,6S)-methyl 5-methyl-2,6-bis(4-nitrophenyl)-1-phenyl-4-(phenylamino)-1,2,5,6-tetrahydropyridine-3-carboxylate (4m)



((2S, 3R, 4S, 6S)-1,2,6-triphenyl-4-(phenylamino)piperidin-3-yl)methanol (7)



5. Absolute configuration assignments and a proposed mechanism

The crystal structure of enantiopure **4l** was obtained (Figure 1), and a single crystal X-ray analysis determined its configuration as (2*R*, 6*S*). CCDC 885330 contains the supplementary crystallographic data for this compound. These data can be obtained free of charge from The Cambridge Crystallographic Data Center via www.ccdc.cam.ac.uk/data_request/cif.





Figure 1. X-ray crystal structure of **4l**

(2*R*,6*S*)-tert-butyl 2,6-bis(4-nitrophenyl)-1-phenyl-4-(phenylamino)-1,2,5,6-tetrahydropyridine-3-carboxylate (**4l**)



Molecular structure of **4l**

The absolute configuration of product **7** was assigned by X-ray crystallographic analysis of *rac*-**7** (Figure 2), which was prepared from *rac*-**4e** with Na/*i*-PrOH. The relative stereochemistry of *rac*-**7** was assigned as (2,3-*cis*, 4,6-*cis*, 3,4-*trans*). As no reaction occurred at the stereogenic center in **4e** with (2*R*, 6*S*) during its transformation into **7**, thus product **7** was assigned as (2*S*, 3*R*, 4*S*, 6*S*). CCDC 898709 contains the supplementary crystallographic data for this compound *rac*-**7**. These data can be obtained free of charge from The Cambridge Crystallographic Data Center via www.ccdc.cam.ac.uk/data_request/cif.







Figure 2. X-ray crystal structure of *rac-7*



**(2*R*,6*S*)-methyl 1,2,6-triphenyl-4-(phenylamino)-1,2,5,6-tetrahydropyridine
-3-carboxylate (4e)**




((2*S*, 3*R*, 4*S*, 6*S*)-1,2,6-triphenyl-4-(phenylamino)piperidin-3-yl)methanol (7**)**



A proposed mechanism for the observed enantioselectivity


The exact mechanism of the reaction is not known at this stage; however a proposed mechanism for the observed enantioselectivity may involve the activation through hydrogen bonding between SPINOL-PA and substrates. We propose a possible model for the asymmetric induction of our catalytic system as shown in Scheme I. Phosphoric acid (S)-**5a** as a bifunctional catalyst combines two intermediates **C** and **D** through hydrogen bonding. In this model, **C** attacks imine **D** from the *Re* face preferentially, leading to a *S*-configuration adduct **F**. The resulting intermediate **F** undergoes an intramolecular 1,4-addition reaction via the sterically less congested conformer would afford the observed 2,6-trans-substituted tetrahydropyridine **4** with defined absolute configuration (*2R*, *6S*).



Scheme I

6. HPLC spectra of products

(2R,6S)-methyl 2,6-bis(4-nitrophenyl)-1-phenyl-4-(phenylamino)-1,2,5,6-tetrahydropyridine
-3-carboxylate (4a)




=====
Area Percent Report
=====

Sorted By : Signal
Multiplier : 1.0000
Dilution : 1.0000
Use Multiplier & Dilution Factor with ISTDs

Signal 1: VWD1 A, Wavelength=254 nm

Peak #	RetTime [min]	Type	Width [min]	Area mAU	*s	Height [mAU]	Area %
1	24.441	MM	2.1740	4757.00977		36.46817	50.0843
2	36.402	MM	3.9163	4740.99023		20.17611	49.9157



=====
Area Percent Report
=====


Sorted By : Signal
Multiplier : 1.0000
Dilution : 1.0000
Use Multiplier & Dilution Factor with ISTDs

Signal 1: VWD1 A, Wavelength=254 nm

Peak #	RetTime [min]	Type	Width [min]	Area mAU	*s	Height [mAU]	Area %
1	22.981	MM	2.2680	4003.69824		29.42196	99.5765
2	31.644	MM	1.9381	17.02847		1.46432e-1	0.4235

(2R,6S)-methyl 2,6-bis(3-nitrophenyl)-1-phenyl-4-(phenylamino)-1,2,5,6-tetrahydropyridine

-3-carboxylate (4b)




Area Percent Report

Sorted By : Signal
Multiplier : 1.0000
Dilution : 1.0000
Use Multiplier & Dilution Factor with ISTDs

Signal 1: VWD1 A, Wavelength=254 nm

Peak #	RetTime [min]	Type	Width [min]	Area mAU	*s	Height [mAU]	Area %
1	9.093	PV	0.5076	5585.54102		162.98126	49.9923
2	32.752	MM	2.3346	5587.25195		39.88652	50.0077



Area Percent Report


Sorted By : Signal
Multiplier : 1.0000
Dilution : 1.0000
Use Multiplier & Dilution Factor with ISTDs

Signal 1: VWD1 A, Wavelength=254 nm

Peak #	RetTime [min]	Type	Width [min]	Area mAU	*s	Height [mAU]	Area %
1	8.822	MM	0.4900	8733.79395		297.04550	95.1398
2	30.922	MM	1.6687	446.16611		4.45630	4.8602

(2R,6S)-methyl 2,6-bis(2-nitrophenyl)-1-phenyl-4-(phenylamino)-1,2,5,6-tetrahydropyridine-

3-carboxylate (4c)




Area Percent Report

Sorted By : Signal
Multiplier : 1.0000
Dilution : 1.0000
Use Multiplier & Dilution Factor with ISTDs

Signal 1: VWD1 A, Wavelength=254 nm

Peak #	RetTime [min]	Type	Width [min]	Area mAU	Height [mAU]	Area %
1	19.631	MM	1.4113	1.01670e4	120.06236	50.0593
2	25.584	EB	1.3867	1.01429e4	106.60125	49.9407



Area Percent Report


Sorted By : Signal
Multiplier : 1.0000
Dilution : 1.0000
Use Multiplier & Dilution Factor with ISTDs

Signal 1: VWD1 A, Wavelength=254 nm

Peak #	RetTime [min]	Type	Width [min]	Area mAU	Height [mAU]	Area %
1	19.408	MM	1.5447	1.63434e4	176.33850	92.4804
2	25.364	MM	1.3404	1328.88916	16.52313	7.5196

(2R,6S)-methyl 2,6-bis(4-cyanophenyl)-1-phenyl-4-(phenylamino)-1,2,5,6-

tetrahydropyridine-3-carboxylate (4d)




Area Percent Report

Sorted By : Signal
Multiplier : 1.0000
Dilution : 1.0000
Use Multiplier & Dilution Factor with ISTDs

Signal 1: VWD1 A, Wavelength=254 nm

Peak #	RetTime [min]	Type	Width [min]	Area mAU	*s	Height [mAU]	Area %
1	7.386	MM	0.5666	1.10213e4		324.19376	50.3771
2	19.454	MM	1.5803	1.08563e4		114.49797	49.6229




Area Percent Report

Sorted By : Signal
Multiplier : 1.0000
Dilution : 1.0000
Use Multiplier & Dilution Factor with ISTDs

Signal 1: VWD1 A, Wavelength=254 nm

Peak #	RetTime [min]	Type	Width [min]	Area mAU	*s	Height [mAU]	Area %
1	7.694	MM	0.5015	7695.73926		255.75510	87.9067
2	19.864	BB	1.0631	1058.70447		14.32628	12.0933

(2R,6S)-methyl 1,2,6-triphenyl-4-(phenylamino)-1,2,5,6-tetrahydropyridine-3-carboxylate (4e)




Area Percent Report

Sorted By : Signal
Multiplier : 1.0000
Dilution : 1.0000
Use Multiplier & Dilution Factor with ISTDs

Signal 1: VWD1 A, Wavelength=254 nm

Peak #	RetTime [min]	Type	Width [min]	Area mAU*s	Height [mAU]	Area %
1	6.610	MM	0.2491	3829.24463	256.21384	49.9781
2	21.138	MM	1.0567	3832.60303	60.44820	50.0219




Area Percent Report

Sorted By : Signal
Multiplier : 1.0000
Dilution : 1.0000
Use Multiplier & Dilution Factor with ISTDs

Signal 1: VWD1 A, Wavelength=254 nm

Peak #	RetTime [min]	Type	Width [min]	Area mAU*s	Height [mAU]	Area %
1	6.629	VV	0.2425	1.45161e4	858.21716	93.7569
2	21.219	MM	0.9938	966.59680	16.21015	6.2431

(2R,6S)-methyl 1-(4-chlorophenyl)-4-((4-chlorophenyl)amino)-2,6-di-p-tolyl-1,2,5,6-tetrahydropyridine-3-carboxylate (4f)




=====
Area Percent Report
=====

Sorted By : Signal
Multiplier : 1.0000
Dilution : 1.0000
Use Multiplier & Dilution Factor with ISTDs

Signal 1: VWD1 A, Wavelength=254 nm

Peak #	RetTime [min]	Type	Width [min]	Area mAU	Area %s	Height [mAU]	Area %
1	7.435	VB	0.3608	5.20428e4	1968.97961	49.9612	
2	17.555	MM	1.6412	5.21236e4	529.31439	50.0388	




=====
Area Percent Report
=====

Sorted By : Signal
Multiplier : 1.0000
Dilution : 1.0000
Use Multiplier & Dilution Factor with ISTDs

Signal 1: VWD1 A, Wavelength=254 nm

Peak #	RetTime [min]	Type	Width [min]	Area mAU	Area %s	Height [mAU]	Area %
1	7.947	VB	0.2387	4056.69287		239.10611	70.6314
2	18.742	BB	1.1295	1686.78027		18.98994	29.3686

(2R,6S)-methyl 1-(4-bromophenyl)-4-((4-bromophenyl)amino)-2,6-diphenyl-1,2,5,6-tetrahydropyridine-3-carboxylate (4g)




Area Percent Report

Sorted By : Signal
Multiplier : 1.0000
Dilution : 1.0000
Use Multiplier & Dilution Factor with ISTDs

Signal 1: VWD1 A, Wavelength=254 nm

Peak #	RetTime [min]	Type	Width [min]	Area mAU*s	Height [mAU]	Area %
1	8.574	FM	0.7083	1.29351e4	304.37094	50.3872
2	13.874	MM	1.8555	1.27363e4	114.40390	49.6128




Area Percent Report

Sorted By : Signal
Multiplier : 1.0000
Dilution : 1.0000
Use Multiplier & Dilution Factor with ISTDs

Signal 1: VWD1 A, Wavelength=254 nm

Peak #	RetTime [min]	Type	Width [min]	Area mAU *s	Height [mAU]	Area %
1	7.596	MM	0.4635	1.80894e4	650.40875	99.0201
2	14.656	MM	2.4590	179.01154	1.21332	0.9799

(2R,6S)-methyl 1-(4-bromophenyl)-4-((4-bromophenyl)amino)-2,6-bis(4-chlorophenyl)-
1,2,5,6-tetrahydropyridine-3-carboxylate (4h)




Area Percent Report

Sorted By : Signal
Multiplier : 1.0000
Dilution : 1.0000
Use Multiplier & Dilution Factor with ISTDs

Signal 1: VWD1 A, Wavelength=254 nm

Peak #	RetTime [min]	Type	Width [min]	Area mAU	Area %	Height [mAU]	Area %
1	4.575	MM	0.3147	5201.82373	50.0930	275.53149	50.0930
2	13.763	BB	1.1066	5182.50000	49.9070	68.63498	49.9070




Area Percent Report

Sorted By : Signal
Multiplier : 1.0000
Dilution : 1.0000
Use Multiplier & Dilution Factor with ISTDs

Signal 1: VWD1 A, Wavelength=254 nm

Peak #	RetTime [min]	Type	Width [min]	Area mAU	Area %	Height [mAU]	Area %
1	4.759	VV	0.2008	6050.39502	95.6813	433.15567	95.6813
2	14.366	MM	1.3179	273.08963	4.3187	3.45356	4.3187

(2R,6S)-methyl-(4-bromophenyl)-4-(4-bromophenylamino)-2,6-bis(4-cyanophenyl)-1,2,5,6-tetrahydropyridine-3-carboxylate (4i)




Area Percent Report

Sorted By : Signal
Multiplier : 1.0000
Dilution : 1.0000
Use Multiplier & Dilution Factor with ISTDs

Signal 1: VWD1 A, Wavelength=254 nm

Peak #	RetTime [min]	Type	Width [min]	Area mAU	Height [mAU]	Area %
1	5.981	VV	0.4615	3.70410e4	1173.23401	50.6596
2	26.465	MM	2.8996	3.60764e4	207.36261	49.3404




Area Percent Report

Sorted By : Signal
Multiplier : 1.0000
Dilution : 1.0000
Use Multiplier & Dilution Factor with ISTDs

Signal 1: VWD1 A, Wavelength=254 nm

Peak #	RetTime [min]	Type	Width [min]	Area mAU	Height [mAU]	Area %
1	6.170	VV	0.4065	8144.86621	283.48550	95.9966
2	26.858	MM	2.4583	339.66638	2.30281	4.0034

(2R,6S)-ethyl 2,6-bis(4-nitrophenyl)-1-phenyl-4-(phenylamino)-1,2,5,6-tetrahydropyridine-3-carboxylate (4j)




Area Percent Report

Sorted By : Signal
Multiplier : 1.0000
Dilution : 1.0000
Use Multiplier & Dilution Factor with ISTDs

Signal 1: VWD1 A, Wavelength=254 nm

Peak #	RetTime [min]	Type	Width [min]	Area mAU	Height [mAU]	Area %
1	34.125	MM	3.2095	183.19328	9.51314e-1	50.2338
2	41.962	MM	4.2533	181.48778	7.11157e-1	49.7662




Area Percent Report

Sorted By : Signal
Multiplier : 1.0000
Dilution : 1.0000
Use Multiplier & Dilution Factor with ISTDs

Signal 1: VWD1 A, Wavelength=254 nm

Peak #	RetTime [min]	Type	Width [min]	Area mAU	Height [mAU]	Area %
1	32.796	MM	3.8940	5276.08594	22.58231	99.4583
2	42.243	MM	2.1168	28.73544	2.26248e-1	0.5417

(2R,6S)-isopropyl 2,6-bis(4-nitrophenyl)-1-phenyl-4-(phenylamino)-1,2,5,6-tetrahydropyridine-3-carboxylate (4k)




Area Percent Report

Sorted By : Signal
Multiplier : 1.0000
Dilution : 1.0000
Use Multiplier & Dilution Factor with ISTDs

Signal 1: VWD1 A, Wavelength=254 nm

Peak #	RetTime [min]	Type	Width [min]	Area mAU	Area %s	Height [mAU]	Area %
1	14.390	MF	1.3646	2958.46606	36.13251	50.4301	
2	17.622	FM	4.4071	2907.99976	10.99738	49.5699	




Area Percent Report

Sorted By : Signal
Multiplier : 1.0000
Dilution : 1.0000
Use Multiplier & Dilution Factor with ISTDs

Signal 1: VWD1 A, Wavelength=254 nm

Peak #	RetTime [min]	Type	Width [min]	Area mAU	Area %s	Height [mAU]	Area %
1	13.105	MM	1.2035	6.14376e4	850.81238	98.0027	
2	17.671	MM	0.5275	1252.09668	39.55929	1.9973	

(2R,6S)-tert-butyl 2,6-bis(4-nitrophenyl)-1-phenyl-4-(phenylamino)-1,2,5,6-tetrahydropyridine-3-carboxylate (4l)




Area Percent Report

Sorted By : Signal
Multiplier : 1.0000
Dilution : 1.0000
Use Multiplier & Dilution Factor with ISTDs

Signal 1: VWD1 A, Wavelength=254 nm

Peak #	RetTime [min]	Type	Width [min]	Area mAU	Area %s	Height [mAU]	Area %
1	4.607	MM	0.2995	1.29038e4		718.08630	50.0283
2	12.711	MM	1.9377	1.28892e4		110.86466	49.9717




Area Percent Report

Sorted By : Signal
Multiplier : 1.0000
Dilution : 1.0000
Use Multiplier & Dilution Factor with ISTDs

Signal 1: VWD1 A, Wavelength=254 nm

Peak #	RetTime [min]	Type	Width [min]	Area mAU	Area %s	Height [mAU]	Area %
1	5.005	VB	0.2727	1623.80005		87.16333	95.7822
2	13.143	MM	1.3729	71.50379		8.68013e-1	4.2178




=====
Area Percent Report
=====

Sorted By : Signal
Multiplier : 1.0000
Dilution : 1.0000
Use Multiplier & Dilution Factor with ISTDs

Signal 1: VWD1 A, Wavelength=254 nm

Peak #	RetTime [min]	Type	Width [min]	Area mAU	Height [mAU]	Area %
1	5.075	MM	0.3016	4220.91357	233.23302	99.6225
2	13.157	MM	0.5078	15.99546	5.24993e-1	0.3775

(2R,5R,6S)-methyl 5-methyl-2,6-bis(4-nitrophenyl)-1-phenyl-4-(phenylamino)-1,2,5,6-tetrahydropyridine-3-carboxylate (4m)




=====
Area Percent Report
=====

Sorted By : Signal
Multiplier : 1.0000
Dilution : 1.0000
Use Multiplier & Dilution Factor with ISTDs

Signal 1: VWD1 A, Wavelength=254 nm

Peak #	RetTime [min]	Type	Width [min]	Area mAU	Height [mAU]	Area %
1	40.572	MF	3.0021	2.77119e4	153.84604	50.7449
2	48.244	FM	3.6340	2.68984e4	123.36295	49.2551




=====
Area Percent Report
=====

Sorted By : Signal
Multiplier : 1.0000
Dilution : 1.0000
Use Multiplier & Dilution Factor with ISTDs

Signal 1: VWD1 A, Wavelength=254 nm

Peak #	RetTime [min]	Type	Width [min]	Area mAU	Area *s	Height [mAU]	Area %
1	41.541	FM	3.0704	8003.65137		43.44580	96.5015
2	51.479	MM	2.2970	290.15692		2.10534	3.4985

((2S,3R,4S,6S)-1,2,6-triphenyl-4-(phenylamino)piperidin-3-yl)methanol (7)




=====
Area Percent Report
=====

Sorted By : Signal
Multiplier : 1.0000
Dilution : 1.0000
Use Multiplier & Dilution Factor with ISTDs

Signal 1: VWD1 A, Wavelength=254 nm

Peak #	RetTime [min]	Type	Width [min]	Area mAU	Area *s	Height [mAU]	Area %
1	8.042	VV	0.4421	6.20321e4		2039.98657	50.0195
2	13.323	MM	0.7335	6.19839e4		1408.41968	49.9805



=====
Area Percent Report
=====

Sorted By : Signal
Multiplier : 1.0000
Dilution : 1.0000
Use Multiplier & Dilution Factor with ISTDs

Signal 1: VWD1 A, Wavelength=254 nm

Peak #	RetTime [min]	Type	Width [min]	Area mAU *s	Height [mAU]	Area %
1	8.215	MM	0.2854	1337.80103	78.12661	6.2820
2	13.464	MM	0.6879	1.99581e4	483.57904	93.7180